(November 09, 2021) The leading biotechnology company Amgen Korea (General Manager: Sang Noh) announced on the 9th that it has signed a memorandum of understanding (MOU) with the Seoul Junggu Office and Seoul Community Chest of Korea for the ‘Golden House Bone Campaign’ to improve the residential environment for the elderly and underprivileged in the Junggu district.
Through the three-way contract, Amgen Korea will establish a long-term partnership with the Seoul Junggu Office and Seoul Community Chest of Korea and deliver a total of 90 million won in donations over 3 years, 30 million won every year from 2021 to 2023. The ‘Golden House Bone Campaign’ is a new corporate social responsibility project prepared by the company to provide fracture prevention education and address the poor residential environment of the elderly and underprivileged class exposed to fracture risk from indoor falls. Amgen Korea will link its work in the ‘Golden House Bone Campaign’ with Junggu Office’s customized welfare program ‘Dream Hearty project’ and discuss various programs with the Junggu Office and Seoul Community Chest of Korea to improve the residential environment for the elderly and the underprivileged class vulnerable to fractures living in the Junggu district.
In particular, Amgen Korea plans to improve the residential environment of low-income or elderly households living in areas with high risk of falls in the Seoul Junggu district. Professional contractors will visit the selected households to diagnose risk of falls within their living environment and improve the residential environments through customization such as removing doorsills in the entrance and rooms that impair mobility of the elderly, installing safety handles and anti-slip mats, and adjusting the height of basin and sinks. In addition, Amgen Korea will discuss various collaborations and measures for fracture prevention until 2023, including education on preventing fractures and falls for middle-aged women and senior citizens living in the Junggu district, and volunteer programs for executives and employees.
Amgen Korea’s GM Sang Noh, Junggu District Mayor Yang-Ho Seo, and Secretary-General of the Seoul Community Chest of Korea Jin-Gon Kim participated in the virtual MOU signing event that was held on the 8th November. Sang Noh, Amgen Korea GM said, “It is a pleasure to be working with the Seoul Junggu Office and Seoul Community Chest of Korea through the ‘Golden House Bone Campaign’ MOU to prevent fractures that arise from indoor falls in the elderly and underprivileged class vulnerable to fractures in the Junggu district. Senior citizens over the age of 60 are often injured in their residential environment, such as in the restroom or bathroom, and 41.5% of them experience bone fractures. Also, special attention should be paid in the winter as many fall accidents occur in the colder season. Under the ‘Golden House Bone Campaign,’ Amgen Korea will continue to strive to improve the residential environment for the elderly in the local community, provide education and support visiting volunteer services to fulfill the corporate mission ‘To Serve Patients.”
Yang-Ho Seo, the Junggu District Mayor, said, “Efforts to minimize the care deficit that has arose in single elderly households became more important due to the reduced care workers and increasing non-face-to-face activity in the prolonged COVID-19 pandemic. It is more meaningful as the long-term partnership with Amgen Korea provides us with an opportunity to interact more closely with the senior citizens in our district while improving the practical residential environment for the elderly. Based on the Dream Hearty project, the Junggu Office plans to conduct various welfare projects that are tailored for the beneficiaries, for the underprivileged who are vulnerable to fractures in the local community.”
Jin-Gon Kim, Secretary-General of the Seoul Community Chest of Korea, said, “The Community Chest of Korea has established partnerships with various stakeholders through the community chest drive with the goal of spreading the philanthropic culture and giving hope to those in need. I believe the residential environment improvement project that we are conducting with Amgen Korea and the Junggu Office will contribute greatly to helping the elderly that are suffering emotionally and physically from the prolonged COVID-19 pandemic. We will do our best to contribute to improving the quality of life as well as bone health of the elderly by working closely with our partners over the next three years.”
Meanwhile, the fund for the campaign was raised through an in-house matching fund quiz that was held in celebration of the ‘World Osteoporosis Day’ on October 20th with the participation of Amgen Korea's executives and employees. Through the ‘Golden House Bone Campaign,’ a corporate social responsibility project designed by the company to prevent fractures within the local community, Amgen Korea will work on various projects with the Seoul Junggu Office and Seoul Community Chest of Korea to improve the residential environment for the elderly exposed to fracture risk and provide fracture prevention education.
# # #
This media release was prepared to provide information on Amgen’s general business activities. Please take care not to risk potential violation of laws and regulations related to pharmaceutical advertising when referring to information contained in the media release.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com.
About Amgen Korea
Amgen Korea was established in November 2015 to further develop Amgen’s clinical pipeline which offers a wide range of products for bone disease, cardiovascular, oncology/hematology, nephrology, inflammation, neuroscience treatment and biosimilars, as well as to provide innovative medicines to patients in Korea who are suffering from severe diseases. As a member of the biotechnical industry, Amgen Korea will continue to contribute to the development of the Korean pharmaceutical industry by carrying forward diversified and positive activities.
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation.
We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful.
A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
Min-Jung Jung (firstname.lastname@example.org)
Jina Lee (email@example.com)
# # #